We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Pfizer, Occidental Petroleum, Charles Schwab, Prudential and S&P Global
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 14, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Pfizer (PFE - Free Report) , Occidental Petroleum (OXY - Free Report) , Charles Schwab (SCHW - Free Report) , Prudential (PRU - Free Report) and S&P Global (SPGI - Free Report) .
Top Analyst Reports for Pfizer, Occidental Petroleum and Charles Schwab
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer, Occidental Petroleum and Charles Schwab. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Pfizer’s shares have underperformed the peer group so far this year (the stock is up +8.3% over this period vs. a +14.5% increase for the Zacks Large-Cap Pharmaceuticals industry). Pfizer’s Q3 results were mixed as it beat earnings estimates but delivered in-line sales. However, the company raised its earnings outlook for the year.
Pfizer is facing headwinds in the form of genericization of key drugs, supply challenges in the legacy Hospira portfolio, pricing pressure and rising competition, which are hurting the top line. Nevertheless, we believe that new products like Ibrance, contribution from acquisitions, cost-cutting efforts and share buybacks should help the company achieve its guidance.
Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years, including around 15 products that have blockbuster potential. Its growing immuno-oncology portfolio offers a strong potential. Bavencio is being considered a key long-term growth driver for Pfizer.
Shares of Occidental Petroleum have outperformed the Zacks Domestic Integrated Oil industry over the last six months, gaining +11.2% vs. +6.7%. The company’s third-quarter earnings topped expectations but total revenues fell behind.
The Zacks analyst likes the fundamental strength of the company, which will help it overcome the adverse impact from natural disasters. Occidental Petroleum will benefit from more oil production from its Permian Resources and from concentrating on high margin production region. The company generates stable cash flow and its Chemical plant will further improve its cash flow.
Occidental Petroleum, like other oil and natural gas companies, faces the risks of cost overruns and development interruptions due to delays in drilling and other approvals, property or border disputes and equipment failures. As expected, Hurricane Harvey adversely impacted income and production in the third quarter as the company had to shut down operation in Texas to ward off the impact of the storm.
Schwab’s shares have outperformed the Zacks Investment Brokers industry over the last three months, gaining +7.7% vs +6.9%. The performance was supported by impressive earnings surprise history, as the company did not lag expectations in any of the trailing four quarters.
The company’s third-quarter 2017 results reflect higher revenues and benefits from rising rates. It remains well positioned to gain from the rising rate environment. Also, initiatives to strengthen trading income are likely to support its profitability in the long run despite the near-term reduction in the same.
However, a continuous rise in expenses (due to rise in compensation costs) remains a key concern for the company. Further, significant dependence on fee-based revenue streams makes us apprehensive.
Other noteworthy reports we are featuring today include Prudential and S&P Global.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Pfizer, Occidental Petroleum, Charles Schwab, Prudential and S&P Global
For Immediate Release
Chicago, IL – November 14, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Pfizer (PFE - Free Report) , Occidental Petroleum (OXY - Free Report) , Charles Schwab (SCHW - Free Report) , Prudential (PRU - Free Report) and S&P Global (SPGI - Free Report) .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for Pfizer, Occidental Petroleum and Charles Schwab
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer, Occidental Petroleum and Charles Schwab. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Pfizer’s shares have underperformed the peer group so far this year (the stock is up +8.3% over this period vs. a +14.5% increase for the Zacks Large-Cap Pharmaceuticals industry). Pfizer’s Q3 results were mixed as it beat earnings estimates but delivered in-line sales. However, the company raised its earnings outlook for the year.
Pfizer is facing headwinds in the form of genericization of key drugs, supply challenges in the legacy Hospira portfolio, pricing pressure and rising competition, which are hurting the top line. Nevertheless, we believe that new products like Ibrance, contribution from acquisitions, cost-cutting efforts and share buybacks should help the company achieve its guidance.
Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years, including around 15 products that have blockbuster potential. Its growing immuno-oncology portfolio offers a strong potential. Bavencio is being considered a key long-term growth driver for Pfizer.
(You can read the full research report on Pfizer here >>>).
Shares of Occidental Petroleum have outperformed the Zacks Domestic Integrated Oil industry over the last six months, gaining +11.2% vs. +6.7%. The company’s third-quarter earnings topped expectations but total revenues fell behind.
The Zacks analyst likes the fundamental strength of the company, which will help it overcome the adverse impact from natural disasters. Occidental Petroleum will benefit from more oil production from its Permian Resources and from concentrating on high margin production region. The company generates stable cash flow and its Chemical plant will further improve its cash flow.
Occidental Petroleum, like other oil and natural gas companies, faces the risks of cost overruns and development interruptions due to delays in drilling and other approvals, property or border disputes and equipment failures. As expected, Hurricane Harvey adversely impacted income and production in the third quarter as the company had to shut down operation in Texas to ward off the impact of the storm.
(You can read the full research report on Occidental Petroleum here >>>).
Schwab’s shares have outperformed the Zacks Investment Brokers industry over the last three months, gaining +7.7% vs +6.9%. The performance was supported by impressive earnings surprise history, as the company did not lag expectations in any of the trailing four quarters.
The company’s third-quarter 2017 results reflect higher revenues and benefits from rising rates. It remains well positioned to gain from the rising rate environment. Also, initiatives to strengthen trading income are likely to support its profitability in the long run despite the near-term reduction in the same.
However, a continuous rise in expenses (due to rise in compensation costs) remains a key concern for the company. Further, significant dependence on fee-based revenue streams makes us apprehensive.
(You can read the full research report on Schwab here >>>).
Other noteworthy reports we are featuring today include Prudential and S&P Global.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.